Showing results (151-160 of 210) with videos related to

Sort By:
Pageof 21
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 14, 2020
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profileKrinio Giannikou, Zachary Zhu, Jaegil Kim, et al.
Neuro-Oncology|February 7, 2019
Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysisJason C H Chiang, Julie H Harreld, Ryuma Tanaka, et al.
Neuro-Oncology|June 2, 2022
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumorSanthosh A Upadhyaya, Olivia Campagne, Catherine A Billups, et al.
Acta Neuropathologica|February 24, 2012
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasMarcel Kool, Andrey Korshunov, Marc Remke, et al.
Cold Spring Harbor Molecular Case Studies|October 13, 2019
Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcomaJamie L Maciaszek, Ninad Oak, Wenan Chen, et al.
Nature|July 20, 2010
Cross-species genomics matches driver mutations and cell compartments to model ependymomaRobert A Johnson, Karen D Wright, Helen Poppleton, et al.
Nature Communications|September 29, 2018
Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptomeMichael Rusch, Joy Nakitandwe, Sheila Shurtleff, et al.
Nature Genetics|March 10, 2009
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastomaPaul A Northcott, Yukiko Nakahara, Xiaochong Wu, et al.
The Journal of Investigative Dermatology|October 1, 2014
The genomic landscape of childhood and adolescent melanomaCharles Lu, Jinghui Zhang, Panduka Nagahawatte, et al.
Cancer Cell|December 24, 2014
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseRebecca M Hill, Sanne Kuijper, Janet C Lindsey, et al.
Pageof 21